Abstract | IMPORTANCE OF THE FIELD: AREAS COVERED IN THIS REVIEW: The current review of the literature (Medline and the Cochrane Library, 1996 - 2009) examines the safety and efficacy of LE/T in the treatment of ocular inflammation. WHAT THE READER WILL GAIN: Studies with either LE or LE/T indicate that LE has a lower risk of IOP elevation compared with C-20 ketone corticosteroids owing to its rapid de-esterification to inactive metabolites. LE also lacks the ability to form Schiff base intermediates with lens proteins, a common first step in cataractogenesis. LE/T was noninferior to dexamethasone 0.1%/ tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis. TAKE HOME MESSAGE:
|
Authors | Timothy L Comstock, Edward J Holland |
Journal | Expert opinion on pharmacotherapy
(Expert Opin Pharmacother)
Vol. 11
Issue 5
Pg. 843-52
(Apr 2010)
ISSN: 1744-7666 [Electronic] England |
PMID | 20210687
(Publication Type: Journal Article, Review)
|
Chemical References |
- Androstadienes
- Anti-Allergic Agents
- Anti-Bacterial Agents
- Drug Combinations
- Ophthalmic Solutions
- Tobramycin
- Loteprednol Etabonate
|
Topics |
- Administration, Topical
- Androstadienes
(administration & dosage, adverse effects, therapeutic use)
- Anti-Allergic Agents
(administration & dosage, adverse effects, therapeutic use)
- Anti-Bacterial Agents
(administration & dosage, adverse effects, therapeutic use)
- Drug Combinations
- Eye Diseases
(drug therapy, physiopathology)
- Humans
- Inflammation
(drug therapy, physiopathology)
- Intraocular Pressure
(drug effects)
- Loteprednol Etabonate
- Ophthalmic Solutions
- Tobramycin
(administration & dosage, adverse effects, therapeutic use)
|